{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:05:51Z","timestamp":1790867151970,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Patients who complete a standard course of anti-tuberculous treatment (ATT) for pulmonary tuberculosis and are declared cured according to the current standard of care commonly have residual metabolic activity (RMA) in their lungs on fluorine-18 fluorodeoxyglucose positron emission tomography\/computed tomography (FDG PER\/CT) imaging. RMA seen in this setting has been shown to be associated with relapse of tuberculosis. The routine clinical use of FDG PET\/CT imaging for treatment response assessment in tuberculosis is hindered by cost and availability. CT is a more readily available imaging modality. We sought to determine the association between CT features suggestive of active tuberculosis and RMA on FDG PET\/CT obtained in patients who completed a standard course of ATT for pulmonary tuberculosis. We prospectively recruited patients who completed a standard course of ATT and declared cured based on negative sputum culture. All patients had FDG PET\/CT within 2 weeks of completing ATT. We determined the presence of RMA on FDG PET images. Among the various lung changes seen on CT, we considered the presence of lung nodule, consolidation, micronodules in tree-in-bud pattern, FDG-avid chest nodes, and pleural effusion as suggestive of active tuberculosis. We determine the association between the presence of RMA on FDG PET and the CT features of active tuberculosis. We include 75 patients with a mean age of 36.09 \u00b1 10.49 years. Forty-one patients (54.67%) had RMA on their FDG PET\/CT while 34 patients (45.33%) achieved complete metabolic response to ATT. There was a significant association between four of the five CT features of active disease, <jats:italic>p<\/jats:italic> &amp;lt; 0.05 in all cases. Pleural effusion (seen in two patients) was the only CT feature of active disease without a significant association with the presence of RMA. This suggests that CT may be used in lieu of FDG PET\/CT for treatment response assessment of pulmonary tuberculosis.<\/jats:p>","DOI":"10.3389\/fmed.2022.791653","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T06:58:02Z","timestamp":1645513082000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Correlation Between CT Features of Active Tuberculosis and Residual Metabolic Activity on End-of-Treatment FDG PET\/CT in Patients Treated for Pulmonary Tuberculosis"],"prefix":"10.3389","volume":"9","author":[{"given":"Ismaheel O.","family":"Lawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kgomotso M. G.","family":"Mokoala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matsontso","family":"Mathebula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Moagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gbenga O.","family":"Popoola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nontando","family":"Moeketsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maphoshane","family":"Nchabeleng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Hikuam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold J.","family":"Ellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hatherill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard P.","family":"Fourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike M.","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/tmi.13371","article-title":"4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India \u2013 a randomsied clinical trial","volume":"25","author":"Velayutham","year":"2020","journal-title":"Trop Med Int Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"CD012918","DOI":"10.1002\/14651858.CD012918.pub2","article-title":"Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis","volume":"12","author":"Grace","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6358","DOI":"10.1128\/JB.182.22.6358-6365.2000","article-title":"Detection of mRNA transcripts and active transcription in persistent mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide","volume":"182","author":"Hu","year":"2000","journal-title":"J Bacteriol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2967\/jnumed.110.083709","article-title":"Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis","volume":"52","author":"Sathekge","year":"2011","journal-title":"J Nucl Med."},{"key":"B8","unstructured":"Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease118490\n            SathekgeM\n            MaesA\n            D'AsselerY\n            VorsterM\n            GongxekaH\n            Van de WieleC\n          10.1007\/s00259-012-2115-y22526957Eur J Nucl Med Mol Imaging.392012"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.5588\/ijtld.12.0010","article-title":"18F-FDG PET\/CT in tuberculosis: an early non-invasive marker of therapeutic response","volume":"16","author":"Martinez","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/nm.4177","article-title":"Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure","volume":"22","author":"Malherbe","year":"2016","journal-title":"Nat Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2967\/jnumed.119.233783","article-title":"c18F-FDG PET\/CT as a non-invasive biomarker for assessing adequacy of treatment and predicting relapse in patients treated for pulmonary tuberculosis","volume":"61","author":"Lawal","year":"2020","journal-title":"J Nucl Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3332\/ecancer.2020.1093","article-title":"Underutilisation of nuclear medicine scans at a regional hospital in Nigeria: need for implementation research","volume":"14","author":"Orunmuyi","year":"2020","journal-title":"Ecancermedicalscience."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S1470-2045(20)30751-8","article-title":"Medical imaging and nuclear medicine: a lancet oncology commission","volume":"22","author":"Hricak","year":"2021","journal-title":"Lancet Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0250616","DOI":"10.1371\/journal.pone.0250616","article-title":"Clinical and CT characteristics of Xpert MTB\/RIF-negative pulmonary tuberculosis","volume":"16","author":"Lee","year":"2021","journal-title":"PLoS ONE."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2147\/IDR.S300754","article-title":"A comparative study of chest computed tomography findings: 1030 cases of drug-sensitive tuberculosis versus 516 cases of drug-resistant tuberculosis","volume":"14","author":"Cheng","year":"2021","journal-title":"Infect Drug Resist."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0231537","DOI":"10.1371\/journal.pone.0231537","article-title":"Clustered micronodules as predominant manifestation on CT: A sign of active but indolently evolving pulmonary tuberculosis","volume":"15","author":"Hong","year":"2020","journal-title":"PLoS ONE."},{"key":"B17","article-title":"Pretoria: Republic of South Africa National Department of Health","year":"2014"},{"key":"B18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1053\/j.semnuclmed.2017.10.005","article-title":"Tuberculosis","volume":"48","author":"Ankrah","year":"2018","journal-title":"Semin Nucl Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.athoracsur.2011.02.039","article-title":"Image characteristics as predictors for thoracoscopic anatomic lung resection in patients with pulmonary tuberculosis","volume":"92","author":"Yen","year":"2011","journal-title":"Ann Thorac Surg."},{"key":"B20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1053\/j.semnuclmed.2017.10.004","article-title":"Monitoring response to therapy","volume":"48","author":"Sathekge","year":"2018","journal-title":"Semin Nucl Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/0037-8682-0230-2016","article-title":"Bacterial immunostat: mycobacterium tuberculosis lipids and their role in the host immune response","volume":"50","author":"Queiroz","year":"2017","journal-title":"Rev Soc Bras Med Trop."},{"key":"B22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1017\/S0950268897007917","article-title":"The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection","volume":"119","author":"Vynnycky","year":"1997","journal-title":"Epidemiol Infect."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","article-title":"The growing burden of tuberculosis: global trends and interactions with the HIV epidemic","volume":"163","author":"Corbett","year":"2003","journal-title":"Arch Intern Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40336-020-00370-4","article-title":"Molecular imaging of cardiovascular inflammation and infection in people living with HIV infection","volume":"8","author":"Lawal","year":"2020","journal-title":"Clin Transl Imaging."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0215412","DOI":"10.1371\/journal.pone.0215412","article-title":"Fluorodeoxyglucose positron emission tomography integrated with computed tomography in carcinoma of the cervix: its impact on accurate staging and the predictive role of its metabolic parameters","volume":"14","author":"Lawal","year":"2019","journal-title":"PLoS ONE."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1097\/MNM.0000000000000905","article-title":"18F-FDG-PET metabolic metrics and International Prognostic Score for risk assessment in HIV-infected patients with Hodgkin lymphoma","volume":"39","author":"Lawal","year":"2018","journal-title":"Nucl Med Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3413\/Nukmed-0965-18-03","article-title":"Prognostic value of pre-treatment F-18 FDG PET metabolic metrics in patients with locally advanced carcinoma of the anus with and without HIV infection","volume":"57","author":"Lawal","year":"2018","journal-title":"Nuklearmedizin."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.791653\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T06:58:05Z","timestamp":1645513085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.791653\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":27,"alternative-id":["10.3389\/fmed.2022.791653"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.791653","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"article-number":"791653"}}